Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
D6405C00002
Phase 2 small_molecule completed
Quick answer
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg for Chronic Kidney Disease is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Chronic Kidney Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed